Dapoxetine

Evidence Level: L5

Predicted Indications: 3

Dapoxetine

Pharmacist Assessment Report

Dapoxetine: selective serotonin reuptake inhibitor (SSRI) → migraine disorder

One-Sentence Summary

Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) that is marketed in India under a number of single-ingredient licences. The TxGNN model predicts it may be useful for migraine disorder, but there are no registered clinical trials and no publication that directly studies dapoxetine in migraine, so the prediction rests on the model score and an indirect mechanistic rationale.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	migraine disorder
TxGNN Prediction Score	0.9934
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data are not available in the data compiled for this report. Pharmacology data show that dapoxetine acts on the serotonin transporter (SERT, gene SLC6A4) and is a short-acting SSRI.

Serotonergic dysregulation is implicated in migraine, and some serotonergic agents and SSRIs have been explored for migraine prevention. This gives a plausible but indirect rationale for the prediction. One review of off-label SSRI uses covers migraine among many other conditions, but it concerns the SSRI class in general and not dapoxetine.

There are also practical concerns. Dapoxetine is designed for short-acting, on-demand dosing, whereas migraine prevention usually needs chronic daily dosing. The very high score is a computational output only and should not be read as clinical evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33998993	2022	Review	Current Neuropharmacology	Review of off-label uses of SSRIs as a class, with migraine among the conditions covered; not specific to dapoxetine
23504864	2013	Cohort	Urologia	Treatment compliance with dapoxetine in premature ejaculation; not related to migraine

Neither publication directly studies dapoxetine in migraine disorder.

India Market Information

The data list 20 valid single-ingredient licences and none cancelled; the list may be partial. The licence records carry no approved-indication text. Main entries:

Authorization Number	Product Name	Dosage Form	Approved Indication
26353	Bold Care 30 Tablet	Strip of 4 tablets	Not recorded
11465	Amjoy 60mg Tablet	Strip of 4 tablets	Not recorded
120971	Long Drive 30mg Tablet	Strip of 4 tablets	Not recorded
60135	Duraject 30mg Tablet	Strip of 2 tablets	Not recorded
58268	Duralast 30 Tablet	Strip of 4 tablets	Not recorded

Safety Considerations

Please refer to the package insert for safety information.

Pharmacology data identify SERT as the target of dapoxetine. No specific drug-interaction records with other drugs are available in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has only a high model score and an indirect serotonergic rationale. No trial or publication directly addresses dapoxetine in migraine, and its on-demand, short-acting profile does not fit the chronic prophylactic dosing usually needed for migraine.

To proceed, the following is needed:

Dapoxetine-specific preclinical or clinical data in migraine
Mechanism-of-action data from DrugBank to support the mechanistic link
Package insert warnings and contraindications from the India licence holders
Assessment of whether a dosing regimen suitable for migraine prevention is feasible
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.